Cash-paying patients, buyers of compounded weight-loss drugs, and makers of branded, generic, and advertised prescription drugs could be affected. Taxpayers, insurers, and investors could also feel the effects through fraud cases and import costs.
Pharmaceutical enforcement here means federal pressure on drug prices, ads, imports, and fraud. Most-favored-nation pricing, called MFN, means matching U.S. prices to the lowest price in other developed nations.
Table of Contents
- Do you pay cash for prescriptions?
- Are drug ads and telehealth offers affected?
- Could import tariffs raise your costs?
- Which companies face fraud and pricing enforcement?
- What limits should you watch?
Do you pay cash for prescriptions?
TrumpRx.gov launched Feb. 5, 2026, for cash-paying patients.
It lists more than 40 drugs from Pfizer, AstraZeneca, Eli Lilly, EMD Serono, and Novo Nordisk at reported 50-80% list discounts, according to Pharmaceutical Technology in the TrumpRx launch report. Uninsured people and people with high deductibles have the most reason to check it. Insured patients may still pay less through their plan than through a cash price.
- List your current drugs, doses, and refill dates
- Compare the TrumpRx cash price with your insurance copay and pharmacy cash price
- Check whether the maker has an MFN deal and U.S. manufacturing commitment
Are drug ads and telehealth offers affected?
On Sept. 9, 2025, President Trump directed HHS and FDA to enforce direct-to-consumer advertising rules more aggressively. Direct-to-consumer means ads aimed at patients rather than doctors. FDA then wrote to every approved drug and biologic sponsor and ordered removal of noncompliant ads and full risk disclosure.
Prescription-drug advertisers and their ad agencies face the widest exposure. FDA issued 28 warning and untitled letters through August 2026, more than four times any full year in 2020-2024, according to EMARKETER in the pharma ad enforcement analysis. Telehealth sellers face separate risk for weight-loss offers. On March 3, 2026, FDA issued 30 warning letters over misleading ads for compounded GLP-1s, including semaglutide and tirzepatide. Patients seeking compounded weight-loss drugs may see offers removed, changed, or restated with risks.
Could import tariffs raise your costs?
Branded or patented imports face pressure to move production to the United States. On Sept. 25, 2025, President Trump imposed a 100% tariff effective Oct. 1, 2025, unless the importer is building U.S. manufacturing. That action later expanded on April 2, 2026, under Section 232 to cover ingredients.
📨 Get Free Accountability Coverage Alerts
Free · No spam · Unsubscribe anytime
Makers with MFN deals plus onshoring commitments can pay 0% until January 2029, versus 20-100% otherwise. Purchasers should watch each maker's deal status because tariff costs can pass through supply contracts. Generic drugs have a temporary shield with a sharp later cliff. Imported generics stay tariff-free from Aug. 1, 2026, for two years, then face 100% for one year and 200% thereafter. Generics matter because they account for over 90% of U.S. prescriptions, so patients, pharmacies, hospitals, and employers buying generics face future price risk.
Which companies face fraud and pricing enforcement?
Drug makers, device firms, providers, and insurers face False Claims Act risk. The Act allows penalties for false claims for federal money, including Medicare and Medicaid. DOJ announced a record $6.8 billion in settlements in fiscal year 2025, driven by health care cases involving pricing and marketing. A July 2, 2025, DOJ-HHS working group targets pharmaceuticals, devices, providers, and insurers.
That increases review of drug pricing, marketing, kickbacks, and reimbursement claims. Manufacturers that reject MFN targets face added threats. On May 12, 2025, President Trump signed Executive Order 14297 directing HHS to issue MFN price targets within 30 days, according to the White House Fact Sheet in the drug-price executive order fact sheet. The order warned of antitrust review, rulemaking, and importation if makers do not voluntarily match the lowest developed-nation prices.
What limits should you watch?
MFN savings are not automatic. Much of the relief remains voluntary or proposed rather than final.
CMS rules from December 2025 tying Part B and Part D rebates to international benchmarks are proposals, not final rules. Medicare and Medicaid savings therefore are not guaranteed. Patients should not assume an announced target equals a lower pharmacy price.
- Ask whether a discount applies to your exact drug, strength, and quantity
- Confirm whether the price is cash-only or also billed to insurance
- Save the offer page, receipt, and plan explanation of benefits
You Might Also Like
- Why Trump Pharmaceutical Enforcement Decisions Is Back in Federal Court
- Trump Pharmaceutical Pricing Agreements: Who Has Authority and Who Can Challenge It?
- Trump Pharmaceutical Enforcement Decisions: What Changed in 2026 and Why It Matters